Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Viemed Healthcare (VMD) EBITDA Margin (2018 - 2025)

Viemed Healthcare's EBITDA Margin history spans 8 years, with the latest figure at 10.99% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 36.0% year-over-year to 10.99%; the TTM value through Dec 2025 reached 8.49%, up 78.0%, while the annual FY2025 figure was 8.49%, 347.0% up from the prior year.
  • EBITDA Margin reached 10.99% in Q4 2025 per VMD's latest filing, up from 7.85% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 12.95% in Q4 2021 to a low of 3.08% in Q2 2022.
  • Average EBITDA Margin over 5 years is 6.76%, with a median of 6.32% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -3953bps in 2021, then surged 379bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 12.95% in 2021, then plummeted by -51bps to 6.35% in 2022, then increased by 8bps to 6.85% in 2023, then skyrocketed by 55bps to 10.63% in 2024, then grew by 3bps to 10.99% in 2025.
  • Per Business Quant, the three most recent readings for VMD's EBITDA Margin are 10.99% (Q4 2025), 7.85% (Q3 2025), and 8.08% (Q2 2025).